Navigation Links
ReSearch Pharmaceutical Services Announces Joint Venture with Asklep in Japan
Date:3/27/2013

FORT WASHINGTON, Pa. and TOKYO, March 27, 2013 /PRNewswire/ -- ReSearch Pharmaceutical Services Inc. ("RPS"), a leading global contract research organization (CRO), and Asklep Inc. ("Asklep"), one of Japan's largest CROs, today announced the creation of a Joint Venture Company (JVC) to deliver leading-edge R&D outsourcing solutions in Japan to the biopharmaceutical and medical device industries. 

The exclusive RPS-Asklep collaboration will leverage RPS' proprietary structures and global footprint to deliver customized solutions across large, mid-size and small and virtual organizations. A breadth of options ranging from embedded, hybrid, and full-service solutions will be available to clients using best-in-class standard operating procedures, processes and systems.  Alan Morgan , RPS' Chief Operating Officer, will assume the role of Chief Executive Officer (CEO) of the JVC, in addition to his current responsibilities.

Commenting upon the announcement Daniel Perlman , CEO and Founder of RPS said, "By combining RPS' innovative approaches to meeting the industry's needs with Asklep's excellent reputation, significant size, and local infrastructure, RPS will be positioned to meet current and future needs across the biopharmaceutical and medical device industries.  Japan is an important market for clinical development and this JVC brings ownership and accountability with mutual success and long-term stability to the benefit of customers."

Hiroshi Ichikawa , President and CEO of Asklep said, "We are delighted to partner with RPS as it provides very unique solutions ranging from embedded, functional and cross-functional programs to enhanced global full-service solutions. Combining RPS' global solutions and Asklep's localized services, we believe the JVC will address an unmet need in Japan."

About RPS  
ReSearch Pharmaceutical Services (RPS), the market leading global provider of innovative outsourcing Clinical Development Solutions, provides comprehensive Phase I-IV services to meet the evolving needs of the Biopharmaceutical, Medical Device and Diagnostic industries, customized by customer type (large, mid-size, and small).  Built organically, RPS is the fastest growing top 10 global Clinical Research Organization (CRO), with more than 5,000 employees and operations in more than 64 countries with proprietary internal structures.  These structures provide both RPS and its partner's greater development flexibility and growth.  RPS is uniquely positioned to provide the following customized clinical development solutions:

  • Large organizations: RPS provides innovative, Embedded, portfolio-wide clinical development solutions  delivering multi-million dollar cost savings, greater quality and the ability to manage more within their portfolio while retaining strategic control and effectively managing regulatory risk. 
  • Midsize organizations: RPS has leveraged its market leading Embedded Clinical Development Solutions expertise providing an innovative model that enables the efficient internal development of a midsize company's product portfolio with greater control and flexibility, accelerated development timelines and substantially reduced costs.
  • Virtual/Small Organizations: RPS provides a comprehensive project based delivery solution with market leading full service processes and tools.  Our in-house drug development expertise combined with outstanding project management means that our clients achieve superior execution on efficiently designed studies.  RPS recruits in excess of 100,000 patients a year with performance ahead of industry leading benchmarks.

For more information about RPS, visit www.rpsweb.com.

About Asklep   
Asklep, Inc., (www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services including monitoring, data management, biostatistics, and comprehensive CRA training. As a member of the Intage Group (http://www.intage.co.jp/), we provide full support service for drug development through medical research and system solutions.


'/>"/>
SOURCE ReSearch Pharmaceutical Services Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Doing Business in China: Research on Chinese Good Manufacturing Practice Regulations for Medical Devices
2. Quantum Materials Corporation Supplies Tetrapod Quantum Dots to U.S. Government Researchers
3. MedNet Solutions To Participate In Multiple Clinical Research Conferences In April 2013
4. Family Tree DNAs Genomics Research Center Facilitates Discovery of Extremely Ancient Root to the Human Y Chromosome Phylogenetic Tree
5. RFID-over-Wi-Fi RTLS Temperature Sensing Solution Protects Clinical Research Specimens at Fred Hutchinson Cancer Research Center
6. Texas Research Institutions Conducted Over 8,200 Clinical Trials of Medicines Since 1999
7. Research and Markets Announces The Release of Neuromodulation Market - Forecasts to 2017
8. New Research Indicating Serious Potential Risks To Cancer Patients From Oncology Drug Shortages
9. Millennium Research Group Sponsors Case Competition at Western University for Second Year
10. Research and Markets Announces the Release of Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and Opportunities
11. Hologics 3D Mammography Technology to be the "New Standard of Care," According to Healthcare Research Firm KLAS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... SAN FRANCISCO , January 23, 2017 The global  ... USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated ... and psychotherapies has resulted in the declining demand for antidepressants in the recent ... ... Grand View Research Logo ...
(Date:1/23/2017)... Januar 2017  ResMed (NYSE: RMD ), ... Medical ( Winter Haven, Florida ) gaben ... die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ResMed ... leisten, um das in Florida ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... United Nations Foundation President ... the Mexico City Policy, also known as the Global Gag Rule, last enacted ... prohibits foreign non-governmental organizations from receiving any U.S. foreign assistance for family planning ...
(Date:1/24/2017)... ... 23, 2017 , ... Texas Home Health, an AccentCare, Inc. ... care service companies: Padre Home Health in Corpus Christi, Texas, and Royalty Personal ... regarded in their respective markets, these two agencies align with Texas Home Health’s ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... men who support them, Dr. Carol Francis, Psychologist in the South Bay ... pay, humane respectful governing for all people and by all people shines as ...
(Date:1/24/2017)... ... , ... The National Council of Alcoholism and Drug Dependence ( NCADD ), ... communities to designate the last full week of January as National Drug and Alcohol ... Myths.” As a community, we can advocate for effective treatment, but also especially ...
(Date:1/23/2017)... ... ... PKF O’Connor Davies , LLP, the nation’s 26th largest accounting and ... will participate in the 40th Annual "Empire State Building Run Up" on Feb. 1 ... a vertical distance equal to about a fifth of a mile, to reach the ...
Breaking Medicine News(10 mins):